Health·August 27, 2026·2 min read

FDA approves first broad RAS-targeted pancreatic cancer drug

Daily pill nearly doubles survival for advanced patients

Logo of the U.S. Food and Drug Administration (FDA).
File photoLogo of the U.S. Food and Drug Administration (FDA).U.S. Food and Drug Administration

The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a once-daily oral treatment from Revolution Medicines for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent chemotherapy. Announced on August 26, the decision came more than six months ahead of the agency's review deadline through the FDA's Real-Time Oncology Review and Commissioner's National Priority Voucher programs, making Rasonque the first approved broad RAS(ON) inhibitor for pancreatic cancer.

The approval was based on the international Phase 3 RASolute 302 trial involving 500 patients whose metastatic disease had progressed after prior treatment. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy, reducing the risk of death by 60%. Median progression-free survival improved to 7.2 months versus 3.6 months, while the objective response rate increased to 30%, compared with 11% for chemotherapy. The most common side effects included rash, diarrhea, mouth sores and other gastrointestinal symptoms, though researchers reported the drug was generally more tolerable than conventional chemotherapy.

More than 90% of pancreatic cancers are driven by abnormal RAS signaling, a target that scientists spent decades trying unsuccessfully to block. Researchers said the approval marks the first successful treatment capable of broadly inhibiting active RAS signaling regardless of a specific companion diagnostic test, opening a new therapeutic approach for one of the deadliest forms of cancer. The disease has an estimated five-year survival rate of about 13% in the United States.

Revolution Medicines said Rasonque is available immediately by prescription with a wholesale list price of $39,800 for a 30-day supply. The company also launched its (ON)Path patient assistance program to help eligible patients access treatment, while regulatory reviews continue in other countries through Project Orbis.

Community discussion
"Do you think accelerated FDA review programs should be expanded for treatments that show major survival benefits against difficult-to-treat diseases?"